Who are Thalidomide (100mg)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abrilada, Humira, Certolizumab Pegol (CZP), Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab, PRECISION dosing Infliximab, Infliximab-Dyyb.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/thalidomide-100mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Thalidomide (100mg) — Competitive Intelligence Brief

Thalidomide (100mg) (Thalidomide (100mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Oncology.

phase 3 Immunomodulator TNF-alpha Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Thalidomide (100mg) (Thalidomide (100mg)) — Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Thalidomide acts as an immunomodulatory agent, inhibiting the release of tumor necrosis factor-alpha (TNF-alpha) and other pro-inflammatory cytokines.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Thalidomide (100mg) TARGET	Thalidomide (100mg)	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	phase 3	Immunomodulator	TNF-alpha
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Certolizumab Pegol (CZP)	Certolizumab Pegol (CZP)	UCB Pharma	marketed	TNF-alpha inhibitor	TNF-alpha
Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab	Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab	University of Helsinki	marketed	Combination immunosuppressive and anti-TNF therapy	Multiple: dihydrofolate reductase (methotrexate), TNF-alpha (infliximab), glucocorticoid receptor (prednisolone)
PRECISION dosing Infliximab	PRECISION dosing Infliximab	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	TNF-alpha inhibitor monoclonal antibody	TNF-alpha (Tumor Necrosis Factor-alpha)
Infliximab-Dyyb	Infliximab-Dyyb	Asan Medical Center	marketed	TNF-alpha inhibitor; monoclonal antibody	TNF-alpha (TNFα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

Actavis Mid-Atlantic LLC · 1 drug in this class
Active Biotech AB · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class
Bayer · 1 drug in this class
Beijing Children's Hospital · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
Chang Gung Memorial Hospital · 1 drug in this class
ALK-Abelló A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thalidomide (100mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/thalidomide-100mg. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab